Loading…
Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study
Summary Background Hip fractures are a major health concern among older persons with Alzheimer's disease, who usually use many concomitant drugs for several diseases. Evidence of the association between proton pump inhibitor use and risk of hip fracture is contradictory. Aim To investigate whet...
Saved in:
| Published in: | Alimentary pharmacology & therapeutics 2018-04, Vol.47 (8), p.1135-1142 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4269-875c5043d3b3cd232db74d02f23d7f9ce264eb06e4efdce7c51619eaaf2d62f03 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4269-875c5043d3b3cd232db74d02f23d7f9ce264eb06e4efdce7c51619eaaf2d62f03 |
| container_end_page | 1142 |
| container_issue | 8 |
| container_start_page | 1135 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 47 |
| creator | Torvinen‐Kiiskinen, S. Tolppanen, A.‐M. Koponen, M. Tanskanen, A. Tiihonen, J. Hartikainen, S. Taipale, H. |
| description | Summary
Background
Hip fractures are a major health concern among older persons with Alzheimer's disease, who usually use many concomitant drugs for several diseases. Evidence of the association between proton pump inhibitor use and risk of hip fracture is contradictory.
Aim
To investigate whether the long‐term use of proton pump inhibitor is associated with risk of hip fractures among community‐dwelling persons with Alzheimer's disease.
Methods
In this nested case‐control study, the nationwide MEDALZ data were utilised. Community‐dwelling persons with Alzheimer's disease who encountered incident hip fracture (N = 4818; mean age 84.1) were included as cases. Four controls were matched for each case at the date of hip fracture (N = 19 235; mean age 84.0). The association between hip fracture and duration of current PPI use (ongoing use during 0‐30 days before the index date), and cumulative duration of use during 10 years before was investigated with conditional logistic regression.
Results
Long‐term or cumulative proton pump inhibitor use was not associated with an increased risk of hip fracture. Current proton pump inhibitor use was associated with an increased risk of hip fracture (adjusted OR 1.12, 95% CI 1.03‐1.22). The risk was increased in short‐term current use ( |
| doi_str_mv | 10.1111/apt.14589 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_490016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2011276399</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4269-875c5043d3b3cd232db74d02f23d7f9ce264eb06e4efdce7c51619eaaf2d62f03</originalsourceid><addsrcrecordid>eNp1kctq3DAUhkVpaaZpF32BIugizcKJLrY8Xg6hl0CgWaRrIUvHHSW25EoWw3SVN2gWfcI8STXxNItAzuZc-Pg5Pz9C7yk5oblO1Tid0LJaNi_QgnJRFYxw8RItCBNNwZaUH6A3MV4TQkRN2Gt0wJqKLEtKF-jPZfCTd3hMw4itW9vWTj7gFAErZ3Cw8Qb7Dq_tiLug9JQCRKwG735i7YchOTtt72_vzAb63ubjCCF6F_HGTmu86n-vwQ4QjiI2NoKKcH_7V2EHcQKD9cN-p72bgu9xnJLZvkWvOtVHeLfvh-jHl89XZ9-Ki-9fz89WF4Uud6aWdaUrUnLDW64N48y0dWkI6xg3dddoYKKElggooTMaal1RQRtQqmNGsI7wQ1TMunEDY2rlGOygwlZ6ZeX-dJMnkGVDCBWZ_zTzY_C_Uv5fDjbqbFo58ClKRihlteBNk9GPT9Brn4LLbnZULeqGih11PFM6-BgDdI8vUCJ3qcqcqnxINbMf9oqpHcA8kv9jzMDpDGxsD9vnleTq8mqW_Afp5rJI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2017679169</pqid></control><display><type>article</type><title>Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study</title><source>Wiley</source><creator>Torvinen‐Kiiskinen, S. ; Tolppanen, A.‐M. ; Koponen, M. ; Tanskanen, A. ; Tiihonen, J. ; Hartikainen, S. ; Taipale, H.</creator><creatorcontrib>Torvinen‐Kiiskinen, S. ; Tolppanen, A.‐M. ; Koponen, M. ; Tanskanen, A. ; Tiihonen, J. ; Hartikainen, S. ; Taipale, H.</creatorcontrib><description>Summary
Background
Hip fractures are a major health concern among older persons with Alzheimer's disease, who usually use many concomitant drugs for several diseases. Evidence of the association between proton pump inhibitor use and risk of hip fracture is contradictory.
Aim
To investigate whether the long‐term use of proton pump inhibitor is associated with risk of hip fractures among community‐dwelling persons with Alzheimer's disease.
Methods
In this nested case‐control study, the nationwide MEDALZ data were utilised. Community‐dwelling persons with Alzheimer's disease who encountered incident hip fracture (N = 4818; mean age 84.1) were included as cases. Four controls were matched for each case at the date of hip fracture (N = 19 235; mean age 84.0). The association between hip fracture and duration of current PPI use (ongoing use during 0‐30 days before the index date), and cumulative duration of use during 10 years before was investigated with conditional logistic regression.
Results
Long‐term or cumulative proton pump inhibitor use was not associated with an increased risk of hip fracture. Current proton pump inhibitor use was associated with an increased risk of hip fracture (adjusted OR 1.12, 95% CI 1.03‐1.22). The risk was increased in short‐term current use (<1 year) (adjusted OR 1.23, 95% CI 1.10‐1.37).
Conclusions
The increased risk of hip fracture was evident only in short‐term proton pump inhibitor use, but no association was found for long‐term or cumulative use. Thus, our findings do not support previous assumptions that long‐term proton pump inhibitor use would be associated with an increased risk of hip fractures.
Linked ContentThis article is linked to Targownik, Torvinen‐Kiiskinen et al, Sugiyama and Zhao et al papers. To view these articles visit https://doi.org/10.1111/apt.14640, https://doi.org/10.1111/apt.14666, https://doi.org/10.1111/apt.14641 and https://doi.org/10.1111/apt.14661.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.14589</identifier><identifier>PMID: 29508411</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aged ; Aged, 80 and over ; Alzheimer Disease - drug therapy ; Alzheimer's disease ; Case-Control Studies ; Female ; Fractures ; Hip ; Hip Fractures - epidemiology ; Hip joint ; Humans ; Independent Living ; Logistic Models ; Male ; Neurodegenerative diseases ; Odds Ratio ; Older people ; Proton pump inhibitors ; Proton Pump Inhibitors - therapeutic use ; Protons ; Risk Factors</subject><ispartof>Alimentary pharmacology & therapeutics, 2018-04, Vol.47 (8), p.1135-1142</ispartof><rights>2018 John Wiley & Sons Ltd</rights><rights>2018 John Wiley & Sons Ltd.</rights><rights>Copyright © 2018 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4269-875c5043d3b3cd232db74d02f23d7f9ce264eb06e4efdce7c51619eaaf2d62f03</citedby><cites>FETCH-LOGICAL-c4269-875c5043d3b3cd232db74d02f23d7f9ce264eb06e4efdce7c51619eaaf2d62f03</cites><orcidid>0000-0002-8926-674X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29508411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:137857711$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Torvinen‐Kiiskinen, S.</creatorcontrib><creatorcontrib>Tolppanen, A.‐M.</creatorcontrib><creatorcontrib>Koponen, M.</creatorcontrib><creatorcontrib>Tanskanen, A.</creatorcontrib><creatorcontrib>Tiihonen, J.</creatorcontrib><creatorcontrib>Hartikainen, S.</creatorcontrib><creatorcontrib>Taipale, H.</creatorcontrib><title>Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Hip fractures are a major health concern among older persons with Alzheimer's disease, who usually use many concomitant drugs for several diseases. Evidence of the association between proton pump inhibitor use and risk of hip fracture is contradictory.
Aim
To investigate whether the long‐term use of proton pump inhibitor is associated with risk of hip fractures among community‐dwelling persons with Alzheimer's disease.
Methods
In this nested case‐control study, the nationwide MEDALZ data were utilised. Community‐dwelling persons with Alzheimer's disease who encountered incident hip fracture (N = 4818; mean age 84.1) were included as cases. Four controls were matched for each case at the date of hip fracture (N = 19 235; mean age 84.0). The association between hip fracture and duration of current PPI use (ongoing use during 0‐30 days before the index date), and cumulative duration of use during 10 years before was investigated with conditional logistic regression.
Results
Long‐term or cumulative proton pump inhibitor use was not associated with an increased risk of hip fracture. Current proton pump inhibitor use was associated with an increased risk of hip fracture (adjusted OR 1.12, 95% CI 1.03‐1.22). The risk was increased in short‐term current use (<1 year) (adjusted OR 1.23, 95% CI 1.10‐1.37).
Conclusions
The increased risk of hip fracture was evident only in short‐term proton pump inhibitor use, but no association was found for long‐term or cumulative use. Thus, our findings do not support previous assumptions that long‐term proton pump inhibitor use would be associated with an increased risk of hip fractures.
Linked ContentThis article is linked to Targownik, Torvinen‐Kiiskinen et al, Sugiyama and Zhao et al papers. To view these articles visit https://doi.org/10.1111/apt.14640, https://doi.org/10.1111/apt.14666, https://doi.org/10.1111/apt.14641 and https://doi.org/10.1111/apt.14661.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer's disease</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Fractures</subject><subject>Hip</subject><subject>Hip Fractures - epidemiology</subject><subject>Hip joint</subject><subject>Humans</subject><subject>Independent Living</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Neurodegenerative diseases</subject><subject>Odds Ratio</subject><subject>Older people</subject><subject>Proton pump inhibitors</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Protons</subject><subject>Risk Factors</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kctq3DAUhkVpaaZpF32BIugizcKJLrY8Xg6hl0CgWaRrIUvHHSW25EoWw3SVN2gWfcI8STXxNItAzuZc-Pg5Pz9C7yk5oblO1Tid0LJaNi_QgnJRFYxw8RItCBNNwZaUH6A3MV4TQkRN2Gt0wJqKLEtKF-jPZfCTd3hMw4itW9vWTj7gFAErZ3Cw8Qb7Dq_tiLug9JQCRKwG735i7YchOTtt72_vzAb63ubjCCF6F_HGTmu86n-vwQ4QjiI2NoKKcH_7V2EHcQKD9cN-p72bgu9xnJLZvkWvOtVHeLfvh-jHl89XZ9-Ki-9fz89WF4Uud6aWdaUrUnLDW64N48y0dWkI6xg3dddoYKKElggooTMaal1RQRtQqmNGsI7wQ1TMunEDY2rlGOygwlZ6ZeX-dJMnkGVDCBWZ_zTzY_C_Uv5fDjbqbFo58ClKRihlteBNk9GPT9Brn4LLbnZULeqGih11PFM6-BgDdI8vUCJ3qcqcqnxINbMf9oqpHcA8kv9jzMDpDGxsD9vnleTq8mqW_Afp5rJI</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Torvinen‐Kiiskinen, S.</creator><creator>Tolppanen, A.‐M.</creator><creator>Koponen, M.</creator><creator>Tanskanen, A.</creator><creator>Tiihonen, J.</creator><creator>Hartikainen, S.</creator><creator>Taipale, H.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><orcidid>https://orcid.org/0000-0002-8926-674X</orcidid></search><sort><creationdate>201804</creationdate><title>Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study</title><author>Torvinen‐Kiiskinen, S. ; Tolppanen, A.‐M. ; Koponen, M. ; Tanskanen, A. ; Tiihonen, J. ; Hartikainen, S. ; Taipale, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4269-875c5043d3b3cd232db74d02f23d7f9ce264eb06e4efdce7c51619eaaf2d62f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer's disease</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Fractures</topic><topic>Hip</topic><topic>Hip Fractures - epidemiology</topic><topic>Hip joint</topic><topic>Humans</topic><topic>Independent Living</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Neurodegenerative diseases</topic><topic>Odds Ratio</topic><topic>Older people</topic><topic>Proton pump inhibitors</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Protons</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Torvinen‐Kiiskinen, S.</creatorcontrib><creatorcontrib>Tolppanen, A.‐M.</creatorcontrib><creatorcontrib>Koponen, M.</creatorcontrib><creatorcontrib>Tanskanen, A.</creatorcontrib><creatorcontrib>Tiihonen, J.</creatorcontrib><creatorcontrib>Hartikainen, S.</creatorcontrib><creatorcontrib>Taipale, H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Torvinen‐Kiiskinen, S.</au><au>Tolppanen, A.‐M.</au><au>Koponen, M.</au><au>Tanskanen, A.</au><au>Tiihonen, J.</au><au>Hartikainen, S.</au><au>Taipale, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2018-04</date><risdate>2018</risdate><volume>47</volume><issue>8</issue><spage>1135</spage><epage>1142</epage><pages>1135-1142</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Hip fractures are a major health concern among older persons with Alzheimer's disease, who usually use many concomitant drugs for several diseases. Evidence of the association between proton pump inhibitor use and risk of hip fracture is contradictory.
Aim
To investigate whether the long‐term use of proton pump inhibitor is associated with risk of hip fractures among community‐dwelling persons with Alzheimer's disease.
Methods
In this nested case‐control study, the nationwide MEDALZ data were utilised. Community‐dwelling persons with Alzheimer's disease who encountered incident hip fracture (N = 4818; mean age 84.1) were included as cases. Four controls were matched for each case at the date of hip fracture (N = 19 235; mean age 84.0). The association between hip fracture and duration of current PPI use (ongoing use during 0‐30 days before the index date), and cumulative duration of use during 10 years before was investigated with conditional logistic regression.
Results
Long‐term or cumulative proton pump inhibitor use was not associated with an increased risk of hip fracture. Current proton pump inhibitor use was associated with an increased risk of hip fracture (adjusted OR 1.12, 95% CI 1.03‐1.22). The risk was increased in short‐term current use (<1 year) (adjusted OR 1.23, 95% CI 1.10‐1.37).
Conclusions
The increased risk of hip fracture was evident only in short‐term proton pump inhibitor use, but no association was found for long‐term or cumulative use. Thus, our findings do not support previous assumptions that long‐term proton pump inhibitor use would be associated with an increased risk of hip fractures.
Linked ContentThis article is linked to Targownik, Torvinen‐Kiiskinen et al, Sugiyama and Zhao et al papers. To view these articles visit https://doi.org/10.1111/apt.14640, https://doi.org/10.1111/apt.14666, https://doi.org/10.1111/apt.14641 and https://doi.org/10.1111/apt.14661.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29508411</pmid><doi>10.1111/apt.14589</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8926-674X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2018-04, Vol.47 (8), p.1135-1142 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_490016 |
| source | Wiley |
| subjects | Aged Aged, 80 and over Alzheimer Disease - drug therapy Alzheimer's disease Case-Control Studies Female Fractures Hip Hip Fractures - epidemiology Hip joint Humans Independent Living Logistic Models Male Neurodegenerative diseases Odds Ratio Older people Proton pump inhibitors Proton Pump Inhibitors - therapeutic use Protons Risk Factors |
| title | Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T16%3A45%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proton%20pump%20inhibitor%20use%20and%20risk%20of%20hip%20fractures%20among%20community%E2%80%90dwelling%20persons%20with%20Alzheimer's%20disease%E2%80%94a%20nested%20case%E2%80%90control%20study&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Torvinen%E2%80%90Kiiskinen,%20S.&rft.date=2018-04&rft.volume=47&rft.issue=8&rft.spage=1135&rft.epage=1142&rft.pages=1135-1142&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.14589&rft_dat=%3Cproquest_swepu%3E2011276399%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4269-875c5043d3b3cd232db74d02f23d7f9ce264eb06e4efdce7c51619eaaf2d62f03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2017679169&rft_id=info:pmid/29508411&rfr_iscdi=true |